Drugs for Conn's Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 292)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Bromocriptine |
Approved, Investigational, Withdrawn |
Phase 4 |
|
25614-03-3 |
31101 |
Synonyms:
(5'a)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman
(5'a)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione
(5'a)-2-Bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
(5'alpha)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman
(5'alpha)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione
(5'alpha)-2-Bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
(5'Α)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman
(5'Α)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione
(5'Α)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
2 Bromo alpha ergocryptine
2 Bromo alpha ergokryptine
2 Bromoergocryptine
2 Bromoergocryptine mesylate
2 Bromoergocryptine methanesulfonate
2 Bromoergokryptine
2-Bromo-a-ergocryptine
2-Bromo-a-ergokryptin
2-Bromo-a-ergokryptine
2-Bromo-alpha-ergocryptine
2-Bromo-alpha-ergokryptin
2-Bromo-alpha-ergokryptine
2-Bromoergocryptine
2-Bromoergocryptine mesylate
2-Bromoergocryptine methanesulfonate
|
2-bromoergocryptine|bromocryptine|CB-154|Parlodel®
2-Bromoergokryptine
2-Bromo-α-ergocryptine
2-Bromo-α-ergokryptin
2-Bromo-α-ergokryptine
Bromergocryptine
Bromocriptin
BROMOCRIPTINA
BROMOCRIPTINE
Bromocriptine mesylate
Bromocriptine methanesulfonate
Bromocriptinum
Bromocryptin
Bromocryptine
Bromoergocriptine
Bromoergocryptine
CB-154
Mesylate, 2-bromoergocryptine
Mesylate, bromocriptine
Methanesulfonate, 2-bromoergocryptine
Parlodel
PLO154
SANDOZ 15-754
|
|
2 |
|
Metformin |
Approved |
Phase 4 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
3 |
|
Losartan |
Approved |
Phase 4 |
|
114798-26-4 |
3961 |
Synonyms:
(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
[<sup>3</sup>H]-losartan
2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
Cozaar
Cozaar®|DuP 753|MK-954
DuP 753
DUP 89
DuP-753
HGP1405
HGP-1405
|
Hyzaar
Lortaan
LOSARTAN
Losartan monopotassium salt
Losartan potassium
Losartic
MK-954
Monopotassium salt, losartan
Potassium, losartan
Salt, losartan monopotassium
|
|
4 |
|
Angiotensin II |
Approved, Investigational |
Phase 4 |
|
68521-88-0, 11128-99-7, 4474-91-3 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
Angiotensin-(1-8) octapeptide
Angiotonin
|
Asp-arg-val-tyr-ile-his-pro-phe
Delivert
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
5 |
|
Captopril |
Approved |
Phase 4 |
|
62571-86-2 |
44093 |
Synonyms:
(2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylate
(2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-2-Methyl-3-sulphanylpropanoyl]pyrrolidine-2-carboxylate
(2S)-1-[(2S)-2-Methyl-3-sulphanylpropanoyl]pyrrolidine-2-carboxylic acid
(S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline
Acediur
Aceplus
Acepress
ACEPRIL
Alopresin
Apopril
C09AA01
Capoten
Capoten®|SQ-14225
Captolane
CAPTOMEX
CAPTOPRIL
Captoprilum
Captoprilum [INN-Latin]
Captopryl
Captoril
Cesplon
|
CP
D-2-Methyl-3-mercaptopropanoyl-L-proline
D-3-Mercapto-2-methylpropanoyl-L-proline
Dilabar
ECOPACE
Garranil
Hipertil
Hypertil
HYTENEZE 12.5
HYTENEZE 25
HYTENEZE 50
KAPLON
L-Captopril
Lopirin
LOPRIL
NOYADA
SA-333
SQ -14225
SQ-14225
Tenosbon
Tensobon
Tensoprel
|
|
6 |
|
Liraglutide |
Approved |
Phase 4 |
|
204656-20-2 |
44147092 16134956 |
Synonyms:
ARG34LYS26-(N-Ε-(Γ-GLU(N-Α-HEXADECANOYL)))-GLP-1[7-37]
LIRAGLUTIDA
LIRAGLUTIDE
Liraglutide (genetical recombination)
Liraglutide (rDNA origin)
LIRAGLUTIDE RECOMBINANT
LIRAGLUTIDUM
N²⁶-(HEXADECANOYL-GAMMA-GLUTAMYLE)-[34-ARGININE]GLP-1-(7-37)-PEPTIDE
N²⁶-(N-HEXADECANOYL-L-GAMMA-GLUTAMYL)-[34-L-ARGININE]GLUCAGON-LIKE PEPTIDE 1-(7-37)-PEPTIDE
NN 2211
|
NN2211
NN-2211
NN-2211|NN2211|Victoza®
NN9924
NN-9924
NNC 90-1170
NNC-90-1170
SAXENDA
VICTOZA
|
|
7 |
|
Nutmeg |
Approved |
Phase 4 |
|
|
|
Synonyms:
|
8 |
|
Amlodipine |
Approved |
Phase 4 |
|
88150-42-9 |
2162 |
Synonyms:
(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid
Almirall brand OF amlodipine besilate
Amlocard
Amlodipine
Amlodipine Benzenesulfonate
Amlodipine besilate
Amlodipine besylate
amlodipine besylate|amlodipine maleate|Copalia® (amlodipine + valsartan)|Katerzia® (amlodipine oral suspension, 1 mg/mL)|Norvasc®|UK-4834011
Amlodipine free base
Amlodipine maleate
Amlodipine maleate (1:1)
Amlodipine, (+-)-isomer
Amlodipine, (+-)-isomer, maleate (1:1)
Amlodipine, (R)-isomer
Amlodipine, (S)-isomer, maleate (1:1)
Amlodipino
Amlodipino [Spanish]
Amlodipinum
|
Amlodipinum [Latin]
Amlodis
Amlor
AMVAZ
Astudal
ASTUDAL 5
CKD-330 COMPONENT AMLODIPINE
Coroval
Eczacibasi brand OF amlodipine besilate
HGP0904
HGP-0904
Istin
Lipinox
Lotrel
Mack brand OF amlodipine besilate
NORVAS
Norvasc
Pelmec
Pfizer brand OF amlodipine besilate
Racemic amlodipine
|
|
9 |
|
Dopamine |
Approved |
Phase 4 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
10 |
|
Somatostatin |
Approved, Investigational |
Phase 4 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
11 |
|
Pasireotide |
Approved |
Phase 4 |
|
396091-73-9 |
56841596 9941444 |
Synonyms:
cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)
Pasireotida
Pasireotide
Pasiréotide
pasireotide diaspartate|Signifor®|SOM 230|SOM 320|SOM-230
|
Pasireotidum
SIGNIFOR
SOM 230
SOM230
SOM-230
|
|
12 |
|
Lactitol |
Approved, Investigational |
Phase 4 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
13 |
|
Cabergoline |
Approved |
Phase 4 |
|
81409-90-7 |
54746 |
Synonyms:
(8b)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8Β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-((6-Allylergolin-8b-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-((6-Allylergolin-8β-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-Allylergoline-8b-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'b-carbonyl)urea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
|
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'β-carbonyl)urea
Cabaser
Cabaser®|Caberlin®
Cabaseril
Cabergolina
Cabergoline
Cabergoline diphosphate
Cabergolinum
CABERLIN
Dostinex
FCE-21336
Galastop
|
|
14 |
|
Eplerenone |
Approved |
Phase 4 |
|
107724-20-9 |
443872 |
Synonyms:
9,11-Epoxy-7-(methoxycarbonyl)-3-oxo-17-pregn-4-ene-21,17-carbolactone
Eplerenon
Eplerenona
EPLERENONE
Epoxymexrenone
|
Inspra
Inspra®|SC-66110
SC-66110
SC-6611O
|
|
15 |
|
Insulin, Globin Zinc |
|
Phase 4 |
|
|
|
16 |
|
Insulin |
|
Phase 4 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
17 |
|
HIV Protease Inhibitors |
|
Phase 4 |
|
|
|
18 |
|
protease inhibitors |
|
Phase 4 |
|
|
|
Synonyms:
|
19 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
20 |
|
Angiotensinogen |
|
Phase 4 |
|
|
16133225 |
Synonyms:
Hypertensinogen
Proangiotensin
Renin substrate
Renin substrate tetradecapeptide
|
Renin-substrate
Serpin a8
SERPINA8
Tetradecapeptide, renin substrate
|
|
21 |
|
Angiotensin-Converting Enzyme Inhibitors |
|
Phase 4 |
|
|
|
22 |
|
Angiotensin Receptor Antagonists |
|
Phase 4 |
|
|
|
23 |
|
Angiotensin II Type 1 Receptor Blockers |
|
Phase 4 |
|
|
|
24 |
|
Giapreza |
|
Phase 4 |
|
|
|
25 |
|
Kallikreins |
|
Phase 4 |
|
|
|
26 |
|
Sitagliptin Phosphate |
|
Phase 4 |
|
654671-77-9 |
|
Synonyms:
JANUMET XR
JANUVIA
MK0431
MK-0431
ONO-5435
|
SITAGLIPTIN MONOPHOSPHATE ANHYDROUS
SITAGLIPTIN MONOPHOSPHATE MONOHYDRATE
SITAGLIPTIN PHOSPHATE
SITAGLIPTIN PHOSPHATE HYDRATE
SITAGLIPTIN PHOSPHATE MONOHYDRATE
|
|
27 |
|
Dipeptidyl-Peptidase IV Inhibitors |
|
Phase 4 |
|
|
|
28 |
|
Incretins |
|
Phase 4 |
|
|
|
29 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
30 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
31 |
|
Mace |
|
Phase 4 |
|
|
|
32 |
|
calcium channel blockers |
|
Phase 4 |
|
|
|
33 |
|
Hormones |
|
Phase 4 |
|
|
|
34 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
35 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
36 |
|
Dopamine agonists |
|
Phase 4 |
|
|
|
37 |
|
Antiparkinson Agents |
|
Phase 4 |
|
|
|
38 |
|
Mineralocorticoids |
|
Phase 4 |
|
|
|
39 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
40 |
|
diuretics |
|
Phase 4 |
|
|
|
41 |
|
Mineralocorticoid Receptor Antagonists |
|
Phase 4 |
|
|
|
42 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
43 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
44 |
|
Terazosin |
Approved |
Phase 3 |
|
63590-64-7 |
5401 |
Synonyms:
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine
Abbott 45975
ABBOTT-45975
ABBOTT-45975|Hytrin®
Adecur
Apo-terazosin
Deflox
Dysalfa
Flotrin
Heitrin
Hexal brand OF terazosin hydrochloride
Hytrin
Hytrin BPH
Hytrine
Magnurol
Novo-terazosin
Nu-terazosin
PMS-Terazosin
Ratio-terazosin
|
Sutif
Tazusin
Terazoflo
Terazosabb
TERAZOSIN
Terazosin azu
Terazosin hexal
Terazosin hydrochloride
Terazosin hydrochloride anhydrous
Terazosin, monohydrochloride, dihydrate
Terazosina
Terazosina alter
Terazosina kern
Terazosina qualix
Terazosine
TÉRAZOSINE
Terazosinum
Zayasel
|
|
45 |
|
Licorice |
Approved |
Phase 2, Phase 3 |
|
|
|
Synonyms:
|
46 |
|
Ketoconazole |
Approved, Investigational |
Phase 3 |
|
65277-42-1, 142128-57-2 |
47576 3823 638701 |
Synonyms:
(+-)-cis-1-Acetyl-4-(P-((2-(2,4-dichlorophenyl)-2-(imidazol-1- ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine
(2S,4R)-1-Acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
(2S,4R)-ketoconazole|COR-003|COR003|Recorlev®
1-[4-[4-[[2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL]METHOXY]PHENYL]-1-PIPERAZINYL]ETHANONE
1-ACETYL-4-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
ABBR KTC
cis-1-Acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1H- imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-ketoconazol
COR003
COR-003
DAKTARIN GOLD
DAKTARIN INTENSIV
DANDRAZOL
DANDRID
EXTINA
Fungarest
Fungoral
J02AB02
Janssen brand OF ketoconazole
KETOCONAZOL
Ketoconazole
|
Ketoconazole janssen brand
KETOCONAZOLUM
Ketoderm
Ketoisdin
KETOPINE
KETOSIDIN
KETOZOLE
LEVOKETOCONAZOLE
Nizoral
NIZORAL A-D
Nizoral®|R-41400
NIZORELLE
NSC 317629
NSC-317629
Orifungal m
Panfungol
Piperazine
R-41400
SID456469
Xolegel
|
|
47 |
|
Diphenhydramine |
Approved, Investigational |
Phase 2, Phase 3 |
|
147-24-0, 58-73-1 |
3100 |
Synonyms:
[2-(DIPHENYLMETHOXY)ETHYL]DIMETHYLAMINE
2-(Benzhydryloxy)-N,N-dimethylethylamine
2-Diphenylmethoxy-N,N-demthylethanamine
2-Diphenylmethoxy-N,N-dimethylethylamine
a-(2-Dimethylaminoethoxy)diphenylmethane
Alledryl
Allerdryl
Allergan
Allergina
alpha-(2-Dimethylaminoethoxy)diphenylmethane
ANTITUSSIVE
b-Dimethylaminoethanol diphenylmethyl ether
b-Dimethylaminoethyl benzhydryl ether
BELDIN
BELIX
Benadryl
BENADRYL PRESERVATIVE FREE
Benadryl®|benzhydramine|dimehydrinate
Bendylate
Benhydramin
Benylin
Benzantin
Benzhydramine
beta-Dimethylaminoethanol diphenylmethyl ether
beta-Dimethylaminoethyl benzhydryl ether
CALADRYL
Citrate, diphenhydramine
COLTEX
DIBENIL
Difenhidramina
Difenhydramine
Dimedrol
Dimedrolum
DIMEHYDRINATE
Dimethylamine benzhydryl ester
Diphamine
Diphantine
|
DIPHEN
DIPHENHYDRAMINE
Diphenhydramine citrate
Diphenhydramine citrate (1:1)
DIPHENHYDRAMINE HCL
Diphenhydramine hydrochloride
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE
Diphenhydraminum
Diphenylhydramin
Diphenylhydramine
Dobacen
Dormin
DREEMON
DYTUSS
FEDRIL
GPPE COUGH EXPECT PAED
GPPE ORAL SOLN
HISTERGAN
HYDRAMINE
Hydrochloride, diphenhydramine
MEDINEX
N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine
NIGHTCALM
NSC-33299
NYTOL
NYTOL ONE-A-NIGHT
O-Benzhydryldimethylaminoethanol
PAXIDORM
Restamin
SILPHEN
SLEEPIA
SYNTEDRIL
TIXYLIX CATARRH
VICKS FORMULA 44
Α-(2-dimethylaminoethoxy)diphenylmethane
Β-dimethylaminoethanol diphenylmethyl ether
Β-dimethylaminoethyl benzhydryl ether
|
|
48 |
|
Promethazine |
Approved, Investigational |
Phase 2, Phase 3 |
|
60-87-7 |
4927 |
Synonyms:
(2-Dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
10-(2-Dimethylaminopropyl)phenothiazine
10-[2-(Dimethylamino)propyl]phenothiazine
Atosil
Diphergan
Diprazin
Hydrochloride, promethazine
Isopromethazine
Lilly 1516
N-(2'-Dimethylamino-2'-methyl)ethylphenothiazine
N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,a-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,Α-trimethyl-10H-phenothiazine-10-ethanamine
NSC-30321
Phenargan
Phenergan
Phenergan®|Sominex®
Phensedyl
Pipolfen
Pipolphen
Proazaimine
Proazamine
|
Promazinamide
Promet
Prometazin
Prometazina
Prometazine
PROMETHACON
Promethazin
PROMETHAZINE
Promethazine hydrochloride
Promethazinum
PROMETHEGAN
Promethiazine
Promezathine
Prothazin
Prothazine
Pyrethia
Remsed
RP-3277
Rumergan
SOMINEX
ZIPAN-25
ZIPAN-50
|
|
49 |
|
Ethanol |
Approved |
Phase 2, Phase 3 |
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
50 |
|
Suvorexant |
Approved, Investigational |
Phase 2, Phase 3 |
|
1030377-33-3 |
57505028 24965990 |
Synonyms:
BELSOMRA
Belsomra®|DORA-analogue|MK 4305|MK-4305
DORA-ANALOGUE
MK 4305
|
MK4305
MK-4305
SUVOREXANT
|
|
Interventional clinical trials:
(show top 50)
(show all 236)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism |
Unknown status |
NCT00451672 |
Phase 4 |
bromocriptine |
2 |
Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? |
Unknown status |
NCT00553722 |
Phase 4 |
Eplerenone;Placebo |
3 |
Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism |
Unknown status |
NCT02127840 |
Phase 4 |
Synacthen infusion during adrenal venous sampling |
4 |
Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy With a Five-year Follow-up |
Completed |
NCT01959711 |
Phase 4 |
|
5 |
Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism |
Completed |
NCT01990560 |
Phase 4 |
Mifepristone |
6 |
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism |
Completed |
NCT00155064 |
Phase 4 |
captopril, Losartan (drug) |
7 |
Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters |
Completed |
NCT03080181 |
Phase 4 |
Pasireotide 0.6 MG/ML |
8 |
A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly |
Completed |
NCT02060383 |
Phase 4 |
Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin |
9 |
An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women |
Recruiting |
NCT05038878 |
Phase 4 |
Elagolix |
10 |
Role of LSD1 in Hypertension in Blacks |
Recruiting |
NCT04840342 |
Phase 4 |
Eplerenone;Amlodipine |
11 |
An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment |
Active, not recruiting |
NCT01794793 |
Phase 4 |
Pasireotide;Cabergoline |
12 |
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study |
Not yet recruiting |
NCT05030545 |
Phase 4 |
Eplerenone |
13 |
Adrenal Artery Ablation for Primary Aldosteronism:A Randomized, Parallel, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Adrenal Artery Ablation(AAA)in the Treatment of Primary Aldosteronism |
Unknown status |
NCT03653845 |
Phase 3 |
Sequenced antihypertensvie drugs with titrated dosage |
14 |
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome |
Completed |
NCT01838551 |
Phase 3 |
Levoketoconazole |
15 |
Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks |
Completed |
NCT02297945 |
Phase 3 |
metyrapone |
16 |
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome |
Completed |
NCT03277690 |
Phase 3 |
Levoketoconazole;Placebo |
17 |
An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome |
Completed |
NCT00569582 |
Phase 3 |
mifepristone |
18 |
An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome |
Completed |
NCT00936741 |
Phase 3 |
mifepristone |
19 |
Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome |
Completed |
NCT01371565 |
Phase 3 |
Mifepristone |
20 |
Towards Cost-effective Management of Patients With Hypertension Due to Primary Aldosteronism: Adrenal Vein Sampling or Ct-scan? |
Completed |
NCT01096654 |
Phase 3 |
|
21 |
The Role of Mineralocorticoid Receptors in Vascular Function |
Completed |
NCT00759525 |
Phase 2, Phase 3 |
Glycyrrhetic Acid;Placebo |
22 |
An Open-label, Prospective, Controlled Clinical Trial on Effects and Safety of Adrenal Artery Ablation (Triple A) for Primary Aldosteronism |
Completed |
NCT03398785 |
Phase 3 |
|
23 |
Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study |
Completed |
NCT01319994 |
Phase 2, Phase 3 |
Metformin;Placebo |
24 |
A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease |
Completed |
NCT02697734 |
Phase 3 |
osilodrostat;osilodrostat Placebo |
25 |
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease |
Completed |
NCT00434148 |
Phase 3 |
Pasireotide |
26 |
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor |
Completed |
NCT00889525 |
Phase 3 |
Cabergoline |
27 |
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease |
Completed |
NCT02180217 |
Phase 3 |
osilodrostat;LCI699 matching placebo |
28 |
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease |
Completed |
NCT01374906 |
Phase 3 |
pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg |
29 |
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape). |
Completed |
NCT01582061 |
Phase 3 |
Pasireotide sub-cutaneous |
30 |
Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant |
Recruiting |
NCT03697109 |
Phase 3 |
Relacorilant |
31 |
Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant |
Recruiting |
NCT04308590 |
Phase 3 |
relacorilant |
32 |
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome |
Active, not recruiting |
NCT03621280 |
Phase 3 |
Levoketoconazole |
33 |
The Efficacy of Suvorexant in the Residential Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial |
Enrolling by invitation |
NCT03412591 |
Phase 2, Phase 3 |
Suvorexant 20 mg |
34 |
An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease |
Withdrawn |
NCT01925092 |
Phase 3 |
mifepristone |
35 |
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma |
Unknown status |
NCT03145285 |
Phase 2 |
Abiraterone Acetate |
36 |
Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in Cushing's Syndrome |
Unknown status |
NCT02611258 |
Phase 2 |
Tadalafil |
37 |
Preoperative Bexarotene Treatment for Cushing's Disease |
Unknown status |
NCT00845351 |
Phase 1, Phase 2 |
Bexarotene |
38 |
Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease |
Unknown status |
NCT02484755 |
Phase 2 |
Gefitinib |
39 |
New Imaging Modalities in the Evaluation of Patients With Ectopic Cushing's Syndrome |
Completed |
NCT00001849 |
Phase 2 |
Pentetreotide;18F-DOPA;18-FDG |
40 |
Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) |
Completed |
NCT03111810 |
Phase 2 |
AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone |
41 |
A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease |
Completed |
NCT00088608 |
Phase 2 |
SOM230 s.c. |
42 |
A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease |
Completed |
NCT02468193 |
Phase 2 |
Osilodrostat |
43 |
Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome |
Completed |
NCT02804750 |
Phase 2 |
CORT125134 |
44 |
A Pilot, Single-blind, Forced-titration Study to Assess the Hemodynamic and Hormonal Effects, Safety and Tolerability of the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism |
Completed |
NCT00732771 |
Phase 2 |
LCI699 |
45 |
Open-label Study on Treatment of Primary Aldosteronism With Everolimus |
Completed |
NCT03174171 |
Phase 2 |
Everolimus 0.75 mg |
46 |
DP13 - A Phase II Study in Patients With Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of DP13, Over an 8-week Treatment Period |
Completed |
NCT04007406 |
Phase 2 |
DP13 |
47 |
Extension to a Multicenter, Open-label Study to Assess the Safety and Efficacy of 600 μg SOM230, Administered Subcutaneously, Bid in Patients With Cushing's Disease |
Completed |
NCT00171951 |
Phase 2 |
Pasireotide |
48 |
A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease |
Completed |
NCT01331239 |
Phase 2 |
LCI699 |
49 |
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor |
Recruiting |
NCT05436639 |
Phase 2 |
SPI-62 dose1;SPI-62 dose 2;SPI-62 dose 3;SPI-62 dose 4;Placebo |
50 |
Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome |
Recruiting |
NCT02019706 |
Phase 2 |
68Ga-DOTATATE;18F-DOPA |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Aminoglutethimide
Fludrocortisone
fluorocortisol acetate
Mitotane
|
pasireotide
Spironolactone
SPIRONOLACTONE PWDR
|
Cochrane evidence based reviews: cushing syndrome
|